DE60237836D1 - Curcuminoid-zusammensetzungen mit synergistischer hemmung der expression und/oder wirkung von cyclooxygenase-2 - Google Patents

Curcuminoid-zusammensetzungen mit synergistischer hemmung der expression und/oder wirkung von cyclooxygenase-2

Info

Publication number
DE60237836D1
DE60237836D1 DE60237836T DE60237836T DE60237836D1 DE 60237836 D1 DE60237836 D1 DE 60237836D1 DE 60237836 T DE60237836 T DE 60237836T DE 60237836 T DE60237836 T DE 60237836T DE 60237836 D1 DE60237836 D1 DE 60237836D1
Authority
DE
Germany
Prior art keywords
cyclooxygenase
expression
effect
synergistic inhibition
curcuminoid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60237836T
Other languages
English (en)
Inventor
John G Babish
Terrence Howell
Linda Pacioretty
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MetaProteomics LLC
Original Assignee
MetaProteomics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MetaProteomics LLC filed Critical MetaProteomics LLC
Application granted granted Critical
Publication of DE60237836D1 publication Critical patent/DE60237836D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Immunology (AREA)
  • Botany (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE60237836T 2001-10-26 2002-10-25 Curcuminoid-zusammensetzungen mit synergistischer hemmung der expression und/oder wirkung von cyclooxygenase-2 Expired - Lifetime DE60237836D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33506201P 2001-10-26 2001-10-26
PCT/US2002/034456 WO2003035007A2 (en) 2001-10-26 2002-10-25 Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2

Publications (1)

Publication Number Publication Date
DE60237836D1 true DE60237836D1 (de) 2010-11-11

Family

ID=23310091

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60237836T Expired - Lifetime DE60237836D1 (de) 2001-10-26 2002-10-25 Curcuminoid-zusammensetzungen mit synergistischer hemmung der expression und/oder wirkung von cyclooxygenase-2

Country Status (14)

Country Link
US (1) US20030096027A1 (de)
EP (2) EP1446136B1 (de)
JP (3) JP2005506996A (de)
KR (1) KR20040054738A (de)
AT (1) ATE482696T1 (de)
AU (2) AU2002348096B2 (de)
CA (1) CA2464334C (de)
DE (1) DE60237836D1 (de)
DK (1) DK1446136T3 (de)
ES (1) ES2353868T3 (de)
MX (1) MXPA04003734A (de)
NZ (1) NZ532560A (de)
PT (1) PT1446136E (de)
WO (1) WO2003035007A2 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030149113A1 (en) 2001-10-12 2003-08-07 Caplan Michael J. Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease
US20040266883A1 (en) * 1999-10-27 2004-12-30 Yale University Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease
US20020076452A1 (en) * 2000-08-01 2002-06-20 Ashni Naturaceuticals, Inc. Combinations of sesquiterpene lactones and ditepene lactones or triterpenes for synergistic inhibition of cyclooxygenase-2
US7901714B2 (en) * 2001-06-20 2011-03-08 Metaproteomics, Llp Treatment modalities for autoimmune diseases
US7815944B2 (en) * 2001-06-20 2010-10-19 Metaproteomics, Llc Anti-inflammatory pharmaceutical compositions for reducing inflammation and the treatment of prevention of gastric toxicity
US20040115290A1 (en) * 2001-06-20 2004-06-17 Tripp Matthew L. Modulation of inflammation by hops fractions and derivatives
US8168234B2 (en) 2001-06-20 2012-05-01 Metaproteomics, Llc Compositions that treat or inhibit pathological conditions associated with inflammatory response
US7205151B2 (en) * 2001-06-20 2007-04-17 Metaproteomics, Llc Complex mixtures exhibiting selective inhibition of cyclooxygenase-2
US7901713B2 (en) * 2001-06-20 2011-03-08 Metaproteomics, Llc Inhibition of COX-2 and/or 5-LOX activity by fractions isolated or derived from hops
US8206753B2 (en) * 2001-06-20 2012-06-26 Metaproteomics, Llc Anti-inflammatory botanical products for the treatment of metabolic syndrome and diabetes
US8142819B2 (en) * 2002-10-21 2012-03-27 Metaproteomics, Llc Synergistic compositions that treat or inhibit pathological conditions associated with inflammatory response
US7270835B2 (en) * 2001-06-20 2007-09-18 Metaproteomics, Llc Compositions that treat or inhibit pathological conditions associated with inflammatory response
US7718198B2 (en) * 2001-06-20 2010-05-18 Metaproteomics, Llc Treatment modalities for autoimmune diseases
CA2464334C (en) * 2001-10-26 2012-01-10 Metaproteomics, Llc Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2
US7279185B2 (en) 2001-10-26 2007-10-09 Metaproteonics, Llc Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2
US8158160B2 (en) 2001-11-13 2012-04-17 Eric Hauser Kuhrts Anti-inflammatory cyclooxygenase inhibitors
CN1870983B (zh) * 2002-02-14 2010-12-01 麒麟麦酒株式会社 用于改善脂质代谢的组合物和食品
EP1496880A4 (de) * 2002-04-24 2007-12-12 Res Dev Foundation SYNERGISTISCHE WIRKUNGEN VON NUKLEÄREN TRANSKRIPTIONSFAKTOR NF-kB HEMMERN UND ANTINEOPLASTISCHE MITTEL
WO2004000229A2 (en) * 2002-06-24 2003-12-31 Research Development Foundation Treatment of human multiple myeloma by curcumin
NZ539642A (en) * 2002-10-21 2007-01-26 Metaproteomics Llc Compositions containing extracts from hops in combination with a second component for treating inflammatory response
JP2005104951A (ja) * 2003-01-17 2005-04-21 Kirin Brewery Co Ltd 血圧降下用組成物および血管柔軟性改善用組成物並びにこれらの機能が付与された食品
ATE421357T1 (de) * 2003-05-22 2009-02-15 Metaproteomics Llc Entzündungshemmende arzneizubereitungen zur entzündungsverminderung und die therapie oder die prophylaxe von der gastrischen toxizität
ITMI20031098A1 (it) * 2003-05-30 2004-11-30 Indena Spa Composti utili nella terapia del morbo di alzheimer e formulazioni che li contengono
CA2536380A1 (en) * 2003-08-26 2005-02-26 Research Development Foundation Osteoclastogenesis inhibitors and uses thereof
JP2005154390A (ja) * 2003-11-28 2005-06-16 Morishita Jintan Kk 肝保護剤
US7914831B2 (en) 2004-02-27 2011-03-29 Metaproteomics, Llc Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines
US20050192356A1 (en) * 2004-02-27 2005-09-01 Babish John G. Synergistic anti-inflammatory pharmaceutical compositions and methods of use
AU2011202586B2 (en) * 2004-02-27 2012-03-22 Metaproteomics, Llc Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines
WO2006043671A1 (ja) * 2004-10-22 2006-04-27 Kirin Beer Kabushiki Kaisha 転写因子Ｎｒｆ２活性化剤およびその機能が付与された食品
KR20070086079A (ko) * 2004-11-13 2007-08-27 메타프로테오믹스, 엘엘씨 사이클로옥시게나제-2의 억제를 나타내는 조성물
EP2248532A1 (de) * 2005-08-09 2010-11-10 Metaproteomics, LLP Proteinkinase-Modulation durch Hopfen- und Akazien-Produkte
CA2632684A1 (en) * 2005-12-09 2007-06-14 Metaproteomics, Llc Protein kinase modulation by hops and acacia products
EP2023747A2 (de) * 2006-05-24 2009-02-18 DSMIP Assets B.V. 3,5-dihydroxy-2,4-cyclohexadienone und ihre derivate, sie enthaltende nahrungsmittelprodukte und angereicherte nahrungsmittel, und ihre verwendungen
US20080031982A1 (en) * 2006-06-20 2008-02-07 Metaproteomics, Llc Tetrahydro-isoalpha acid based protein kinase modulation cancer treatment
US20080051466A1 (en) * 2006-06-20 2008-02-28 Metaproteomics, Llc Isoalpha acid based protein kinase modulation cancer treatment
CA2663954A1 (en) * 2006-09-19 2008-04-24 Human Biomolecular Research Institute Curcumin analogs, diagnostic methods and genetic markers for diagnosing and treating alzheimer's disease
MX2009010049A (es) * 2007-03-19 2010-03-04 Metaproteomics Llc Metodos y composiciones para promover la salud de huesos y articulaciones.
WO2008120220A1 (en) * 2007-04-03 2008-10-09 Ganga Raju Gokaraju Synergistic anti-inflammatory and antioxidant dietary supplement compositions
WO2008140842A1 (en) * 2007-05-11 2008-11-20 Metaproteomics, Llc Methods and compositions for heavy metal detoxification
WO2009066303A2 (en) * 2007-11-22 2009-05-28 Ganga Raju Gokaraju New synergistic phytochemical composition for the treatment of obesity
KR20100131969A (ko) * 2007-12-10 2010-12-16 메타프로테오믹스, 엘엘씨 암, 혈관신생 및 이와 관련된 염증 경로의 치환된 1,3-시클로펜타디온 다중-표적 단백질 키나아제 조절제
NZ588927A (en) * 2008-04-02 2013-02-22 Metaproteomics Llc Substituted 1,3-cyclopentadione attenuated endothelial inflammation and endothelial-monocyte interactions
WO2009126320A1 (en) * 2008-04-11 2009-10-15 Betal, Llc Xanthohumol compositions and methods for treating skin diseases or disorders
JP6049639B2 (ja) * 2011-12-28 2016-12-21 マルハニチロ株式会社 クロロフィルｃ含有脱顆粒抑制剤
JP6163084B2 (ja) * 2013-11-11 2017-07-12 キリン株式会社 認知症の予防、治療及び／又は認知機能を改善する組成物、及びこれを用いた医薬、食品
JP6242746B2 (ja) * 2014-05-26 2017-12-06 キリン株式会社 記憶学習機能を向上する医薬、食品、組成物
CN107582962A (zh) * 2017-06-01 2018-01-16 合肥远志医药科技开发有限公司 一种用于慢性萎缩性胃炎的配方及其提取工艺

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07149628A (ja) * 1993-11-30 1995-06-13 Suntory Ltd 脂質代謝改善剤
US5494668A (en) * 1994-07-11 1996-02-27 Patwardhan; Bhushan Method of treating musculoskeletal disease and a novel composition therefor
JPH0873369A (ja) * 1994-09-01 1996-03-19 Fuairudo:Kk 健康茶
US6346519B1 (en) * 1998-09-09 2002-02-12 Advanced Medical Instruments Method and composition for treating arthritis
US20010051184A1 (en) * 1999-05-20 2001-12-13 Madalene C.Y. Heng Method for using soluble curcumin to inhibit phosphorylase kinase in inflammatory diseases
US6143303A (en) * 1999-08-14 2000-11-07 Janakiram; Chodavarapu Analgesic anti-inflammatory composition and method of preparing from dodonaea sp
DE10031955A1 (de) * 2000-06-30 2002-01-17 Deutsches Krebsforsch Curcumin-Derivate mit gegenüber Curcumin verbesserter Wasserlöslichkeit und diese enthaltende Arzneimittel
US6391346B1 (en) * 2001-04-05 2002-05-21 Thomas Newmark Anti-inflammatory, sleep-promoting herbal composition and method of use
CA2464334C (en) * 2001-10-26 2012-01-10 Metaproteomics, Llc Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2
US7914831B2 (en) * 2004-02-27 2011-03-29 Metaproteomics, Llc Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines

Also Published As

Publication number Publication date
EP1446136B1 (de) 2010-09-29
CA2464334A1 (en) 2003-05-01
CA2464334C (en) 2012-01-10
EP2253314A2 (de) 2010-11-24
JP2005506996A (ja) 2005-03-10
AU2008202916B8 (en) 2010-06-10
WO2003035007A3 (en) 2003-09-18
JP2011068680A (ja) 2011-04-07
ATE482696T1 (de) 2010-10-15
ES2353868T3 (es) 2011-03-07
DK1446136T3 (da) 2011-01-10
NZ532560A (en) 2005-02-25
PT1446136E (pt) 2010-12-29
WO2003035007A2 (en) 2003-05-01
US20030096027A1 (en) 2003-05-22
EP2253314A3 (de) 2012-08-01
AU2008202916A1 (en) 2008-07-24
JP2011093918A (ja) 2011-05-12
AU2008202916B2 (en) 2010-06-03
MXPA04003734A (es) 2005-06-20
EP1446136A4 (de) 2007-01-10
AU2002348096B2 (en) 2008-04-03
KR20040054738A (ko) 2004-06-25
EP1446136A2 (de) 2004-08-18

Similar Documents

Publication Publication Date Title
DE60237836D1 (de) Curcuminoid-zusammensetzungen mit synergistischer hemmung der expression und/oder wirkung von cyclooxygenase-2
PT1005271E (pt) Composicao biocida sinergica
EA200700382A1 (ru) Фунгицидные композиции
BR0312479A (pt) Composição de tratamento dos cabelos e/ou couro cabeludo, método de tratamento de caspa e uso de óleo de manjericão
DK1369039T3 (da) Synergistiske herbicide fremgangsmåder
DE602004018338D1 (de) Prävention und behandlung von durch entzündung ausgelöstem und/oder immunvermitteltem knochenschwund
ATE188341T1 (de) Konservierungsmittel und verfahren zur behandlung von holz
DE602004030535D1 (de) Verfahren zur behandlung von schmerzen durch verabreichung eines nervenwachstumsfaktor-antagonisten und eines nsaid und diese enthaltende zusammensetzung
DK1545587T3 (da) Lactoferrinsammensætninger og fremgangsmåder til behandling af diabetiske sår
ATE347401T1 (de) Kosmetische verwendung einer zusammensetzung mit mindestens einem oxazolin als wirkstoff, als abnehmprodukt und/oder zur prävention und/oder behandlung von cellulite
DK1664041T3 (da) Phenylcarboxamidforbindelser, der er egnede til behandling af smerter
BRPI0502841A (pt) uso de produtos de legume para o tratamento e prevenção de dano à pele induzido por radioterapia
DE60316821D1 (de) Aminobenzothiazolverbindungen mit nos-hemmender wirkung
BRPI0307808A2 (pt) composição inibidora da lipase
EA200801140A1 (ru) Фунгицидные смеси
DE60312004D1 (de) Zusammensetzungen enthaltend mindestens kürbisöl und borretschöl, deren verwendung als arzneimittel, dermatikum oder dermatokosmetische zusammensetzung
ES2079817T3 (es) Composicion para el tratamiento de las uñas que comprende un aminoacido sulfurado.
AR030487A1 (es) Una composicion herbicida sinergica de un compuesto de dehidrobenzotiofeno y un inhibidor del fotosistema ii y el metodo para el control sinergico de plantas no deseables con dicha composicion
ATE486567T1 (de) Orale zusammensetzung mit einer ersten zusammensetzung (a) und einer zweiten zusammensetzung (b) zur verwendung als gemische zur getrennten oder aufeinanderfolgenden verwendung in der kosmetischen behandlung des menschlichen körpers
DE60128009D1 (de) Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
BR0316254A (pt) Misturas e agentes fungicidas, processo para combater fungos nocivos fitopatogênicos, e, uso dos compostos
BRPI0411168A (pt) composição para o tratamento dos cabelos, usos de uma composição e método de tratamento dos cabelos
DE69424679T2 (de) Zusammensetzung zur behandlung oder vorbeugung von herpes
DE60015133D1 (de) Synergistische zusammensetzung von bioziden
ATE400259T1 (de) Verwendung von colipase-lipase-hemmern bei der herstellung einer pharmazeutischen zusammensetzung zur prävention von adipositas

Legal Events

Date Code Title Description
R082 Change of representative

Ref document number: 1446136

Country of ref document: EP

Representative=s name: JONES DAY RECHTSANWAELTE PATENTANWAELTE, DE